IDH1 and glioblastoma: Recently, the WHO classification has been modified to include molecular criteria, such as IDH mutations for diffuse astrocytoma and GBM, or the epigenetic mark H3K27M mutation for diffuse midline glioma, to provide more precise diagnosis and treatment.6 However, the quest for potential therapeutic targets remains unfulfilled;7, 8 thus, new strategies are emerging to explore the molecular basis of brain tumour development for clinical exploitation.